

Atty Dkt. No.: UCAL-222
 USSN: 10/017,718
 Exhibit 1

FACSIMILE NO. 571-273-0733		
DECLARATION UNDER 37 C.F.R. § 1.132 AND 37 C.F.R. § 1.57 (f)	Attorney Docket Confirmation No.	UCAL-222 5282
	First Named Inventor	K.H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	T.N. Ton
	Title	Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
Address to: Commissioner for Patents Alexandria, VA 22313-1450		

CONSIDERED
 4.11.06
 TNT

Dear Sir:


1. I, Paula A. Borden, declare and say I am agent of record in the above-captioned patent application.
2. An amendment, filed on July 6, 2004 in this application, amended the specification and drawings to include the following amendatory material: 1) new Figures 5A and 5B; and 2) a new paragraph on page 17, between paragraphs 0068 and 0069. The amendatory material was added to include material incorporated by reference in the specification. Specifically, paragraph 0068 of the instant specification refers to Weisgraber ((1994) *Adv. Protein Chem.* 45:249-302; "Weisgraber") for the disclosure of amino acid sequences of apoE from a variety of species. New Figures 5A and 5B correspond to Figure 1 on page 252 of Weisgraber, which Figure 1 provides amino acid sequences of apoE from a variety of species; and the new paragraph corresponds to the legend to Figure 1 of Weisgraber. The April 20, 2004 Office Action requested that the disclosure be amended to include the material incorporated by reference to Weisgraber.

Atty Dkt. No.: UCAL-222
USSN: 10/017,718
Exhibit 1

3. As provided for in MPEP §608.01(p) and 37 C.F.R. §1.57(f), I declare that the amendatory material consists of the same material incorporated by reference in this application; and that the amendatory material adds no new matter.

4. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that those statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Apr. 6, 2006
Date



The signature is handwritten in black ink, appearing to read "Paula A. Borden". It is written over a stylized oval outline.

Paula A. Borden